
Breast Cancer
Jan 23, 2025, 02:32
The safety and effectiveness of sacituzumab govitecan with trastuzumab for HER2+ Metastatic Breast Cancer
Dana-Farber’s Breast Oncology Center shared on X:
“The SATEENtrial led by Dana-Farber’s Breast Oncology Center is a multi-center, single-arm phase II trial to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab for HER2+ Metastatic Breast Cancer.
For more information call 877-338-7425 or visit.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29